BMC Cancer

1. LI B, Lou G, Zhang J, Cao N, et al
   Retraction Note: Repression of LncRNA PART1 attenuates ovarian cancer cell viability, migration and invasion through the miR-503-5p/FOXK1 axis.
   BMC Cancer. 2026;26:105.
   

   >> Share

   
   

   
   Cancer

2. SHAN Y, Ding B, Ji F, Lin H, et al
   T-cell receptor-like chimeric antigen receptor T cells targeting mesothelin: A first-in-human dose-escalation trial for platinum-resistant advanced ovarian cancer.
   Cancer. 2026;132:e70279.
   

   >> Share

   
   

   
   Cancer Lett

3. XU H, Zeng S, Wang M, Wang Y, et al
   Cytoplasmic SIRT1 enhances the stemness of polyploid giant cancer cells by promoting beta-catenin protein stability and nuclear accumulation in ovarian carcinoma upon neoadjuvant chemotherapy.
   Cancer Lett. 2025 Dec 1:218193. doi: 10.1016/j.canlet.2025.218193.
   

   >> Share

   
   

   
   J Clin Oncol

4. SLOMOVITZ BM, Weroha SJ, Deng W, Chon HS, et al
   Phase II Trial of Ribociclib Plus Letrozole in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary, Fallopian Tube, or Peritoneum: A GOG Partners Trial (GOG 3026).
   J Clin Oncol. 2026;44:153-163.
   

   >> Share

   
   

Free Medical Abstracts
Privacy Policy
Sponsors
Share